CytomX Therapeutics Inc.

Contributing Author

Recent Articles by CytomX Therapeutics Inc.

May-29	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference CTMX GlobeNewswire
May-19	CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma CTMX GlobeNewswire
May-12	CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock CTMX GlobeNewswire
May-12	CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) CTMX GlobeNewswire
May-12	CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update CTMX GlobeNewswire
May-05	CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 CTMX GlobeNewswire